News on biomarker discovery and validation for research and diagnostic use in genetics, genomics, and molecular diagnostics.
Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
The partners aim to identify microRNAs that can be used to identify patients likely to respond to PD-L1-targeting cancer drugs.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The companies have expanded their relationship to include the development and automation of assays for clinical trials and clinical testing.
4D will use Owlstone's breath biomarker services to help advance development of its live bacteria-based drugs candidates.